Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

S.W. Lam, S.M. de Groot, A.H. Honkoop, A. Jager, A.J. ten Tije, M.M.E.M. Bos, S.C. Linn, J. Bosch, J.R. Kroep, J.J. Braun, H. van Tinteren, E. Boven

Research output: Contribution to journalArticleAcademicpeer-review

29 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)3077-3088
JournalEuropean Journal of Cancer
Issue number18
Publication statusPublished - 2014

Cite this